BioAge Labs, Inc. (BIOA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the 2025 Annual Meeting of Stockholders held by BioAge Labs, Inc. on June 5, 2025. The Company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol "BIOA".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes and Voting Results
Stockholders approved two key proposals at the Annual Meeting:
- Director Elections: Three Class I Directors were elected to three-year terms expiring at the 2028 Annual Meeting. The vote tallies were as follows:
- Kristen Fortney, Ph.D.: 17,302,916 shares For; 2,080,603 shares Withheld; 6,051,187 Broker Non-Votes.
- Eric Morgen, M.D.: 17,188,188 shares For; 2,195,331 shares Withheld; 6,051,187 Broker Non-Votes.
- Vijay Pande, Ph.D.: 17,219,427 shares For; 2,164,092 shares Withheld; 6,051,187 Broker Non-Votes.
- Auditor Ratification: Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The vote tally was 25,372,549 shares For, 55,336 shares Against, and 6,821 shares Abstaining.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation of the new Board of Directors composition and term expiration dates (2028).
- Verification of KPMG LLP's engagement as the independent auditor for the 2025 fiscal year.
- Analysis of the significant number of broker non-votes (over 6 million) regarding director elections, which may indicate specific proxy voting instructions or lack thereof.